AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25917017 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation therapy on the suprahyoid muscles (SM group, n = 66)
Number of subjects: 132
Study 25917017 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation therapy with electrodes on both suprahyoid and infrahyoid muscles (SI group, n = 66)
Number of subjects: 132
Study 23816490 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity prevention intervention
Number of subjects: 421
Study 23816490 — intervention group
Group type: COMPARATOR
Intervention: Contact Control condition
Number of subjects: 421
Study 20030775 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength training (S)
Number of subjects: 96
Study 20030775 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (SE)
Number of subjects: 96
Study 20030775 — intervention group
Group type: COMPARATOR
Intervention: Endurance training (E)
Number of subjects: 96
Study 20030775 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 96
Study 19751115 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (10/160 mg o.d.)
Number of subjects: 944
Study 19751115 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (10 mg o.d.)
Number of subjects: 944
Study 16954960 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg for 14 days)
Number of subjects: 1110
Study 16954960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1110
Study 15274104 — intervention group
Group type: EXPERIMENTAL
Intervention: A/C + VG
Number of subjects: 18
Study 15274104 — intervention group
Group type: COMPARATOR
Intervention: A/C
Number of subjects: 18
Study 11813617 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 300 micrograms t.i.d. for seven days
Number of subjects: 120
Study 11813617 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 200 micrograms t.i.d. for seven days
Number of subjects: 120
Study 11813617 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 100 micrograms t.i.d. for seven days
Number of subjects: 120
Study 9284731 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.036 U/kg.day
Number of subjects: 13
Study 9284731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8329164 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Interplak)
Number of subjects: 20
Study 8329164 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual toothbrush (Butler 311)
Number of subjects: 20
Study 3819198 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous insertion
Number of subjects: 101
Study 3819198 — intervention group
Group type: COMPARATOR
Intervention: Surgical insertion
Number of subjects: 101
Study 29537647 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE, 0.625 mg/day)
Number of subjects: 8
Study 29537647 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE, 0.625 mg/day) + medroxyprogesterone acetate (MPA, 2.5 mg/day)
Number of subjects: 8
Study 26640129 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 12
Study 26640129 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 12
Study 25365268 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive assessment by a screening radiologist
Number of subjects: 366
Study 25365268 — intervention group
Group type: COMPARATOR
Intervention: Usual care (multidisciplinary hospital assessment)
Number of subjects: 366
Study 22626586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (12 hour maximum shift schedule compliant with 2011 restrictions)
Number of subjects: 11
Study 22626586 — intervention group
Group type: COMPARATOR
Intervention: Control group (every fourth night, 30-hour call schedule)
Number of subjects: 11
Study 22626586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 11
Study 22626586 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study 20393978 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane alone or following tamoxifen
Number of subjects: 9779
Study 20393978 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery with radiotherapy
Number of subjects: 9779
Study 20393978 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection
Number of subjects: 9779
Study 19063808 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based telediabetes programs
Number of subjects: 0
Study 16085942 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green‐assisted internal limiting membrane peeling
Number of subjects: 49
Study 16085942 — intervention group
Group type: COMPARATOR
Intervention: No internal limiting membrane peeling
Number of subjects: 49
Study 12369293 — intervention group
Group type: EXPERIMENTAL
Intervention: Misgav‐Ladach method
Number of subjects: 110
Study 12369293 — intervention group
Group type: COMPARATOR
Intervention: Pfannenstiel method
Number of subjects: 110
Study 12369293 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 110
Study 11360606 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 0.75 mg taken twice with 12 hours apart
Number of subjects: 1276
Study 11360606 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone (Mife-) single dose of 10 mg and placebo 12 hours after
Number of subjects: 1276
Study 7484025 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 0.5 times the ED50 doses of mivacurium and pancuronium (cMP)
Number of subjects: 70
Study 7484025 — intervention group
Group type: COMPARATOR
Intervention: cMP administered to the same IV-line
Number of subjects: 70
Study 7484025 — intervention group
Group type: COMPARATOR
Intervention: cMP administered to two separate IV-lines in opposite hands
Number of subjects: 70
Study 7484025 — intervention group
Group type: EXPERIMENTAL
Intervention: cMP
Number of subjects: 70
Study 1322075 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (125 mg four times daily for 10 days)
Number of subjects: 30
Study 1322075 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (500 mg twice daily for 10 days)
Number of subjects: 30
Study 1322075 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three times daily for 10 days)
Number of subjects: 30
Study 1322075 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 30
Study 6095356 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 0
Study 6095356 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic sodium lactate
Number of subjects: 0
Study 6095356 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 0
Study 6095356 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (after treatment)
Number of subjects: 0
Study 6095356 — intervention group
Group type: COMPARATOR
Intervention: Nonpsychiatric control subjects
Number of subjects: 0
Study 31663443 — intervention group
Group type: EXPERIMENTAL
Intervention: ADC gel
Number of subjects: 20
Study 31663443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29063592 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (Ω3)
Number of subjects: 95
Study 29063592 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (Ω3) alone
Number of subjects: 95
Study 29063592 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (Ω3) combined with psychoeducational psychotherapy (PEP)
Number of subjects: 95
Study 29063592 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational psychotherapy (PEP) monotherapy
Number of subjects: 95
Study 24578470 — intervention group
Group type: EXPERIMENTAL
Intervention: icodextrin
Number of subjects: 53
Study 24578470 — intervention group
Group type: COMPARATOR
Intervention: Control (glucose-based dialysis solution)
Number of subjects: 53
Study 22339101 — intervention group
Group type: EXPERIMENTAL
Intervention: Hegu acupuncture
Number of subjects: 187
Study 22339101 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard acupuncture
Number of subjects: 187
Study 22339101 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 187
Study 19446314 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan
Number of subjects: 274
Study 19446314 — intervention group
Group type: COMPARATOR
Intervention: Treosulfan
Number of subjects: 274
Study 17885238 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (retreatment)
Number of subjects: 323
Study 17885238 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (retreatment) for small aneurysms (< or =10 mm) with small necks (< or =4 mm)
Number of subjects: 323
Study 17885238 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk group (n = 128)
Number of subjects: 323
Study 17885238 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with residual aneurysm after the first treatment
Number of subjects: 323
Study 17885238 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment procedures
Number of subjects: 323
Study 15070873 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (0.1 mg triptorelin)
Number of subjects: 138
Study 15070873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 11576319 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-hypertensive treatment for 3 months with a calcium-antagonist in randomized combination with either an ACE inhibitor or a beta-blocker
Number of subjects: 29
Study 11576319 — intervention group
Group type: COMPARATOR
Intervention: Baseline hypertensives
Number of subjects: 29
Study 11576319 — intervention group
Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 29
Study 9592630 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 96
Study 9592630 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 96
Study 9592630 — intervention group
Group type: COMPARATOR
Intervention: Other antidepressants or lithium
Number of subjects: 96
Study 9592630 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 96
Study 8169616 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nicardipine (0.15 mg/kg/hr)
Number of subjects: 365
Study 8169616 — intervention group
Group type: COMPARATOR
Intervention: Low-dose nicardipine (0.075 mg/kg/hr)
Number of subjects: 365
Study 8169616 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nicardipine
Number of subjects: 365
Study 8169616 — intervention group
Group type: COMPARATOR
Intervention: Low-dose nicardipine
Number of subjects: 365
Study 3154680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 25
Study 3154680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 30115326 — intervention group
Group type: EXPERIMENTAL
Intervention: Claroideoglomus etunicatum
Number of subjects: 0
Study 30115326 — intervention group
Group type: EXPERIMENTAL
Intervention: Gigaspora albida
Number of subjects: 0
Study 30115326 — intervention group
Group type: EXPERIMENTAL
Intervention: C. etunicatum + G. albida
Number of subjects: 0
Study 30115326 — intervention group
Group type: COMPARATOR
Intervention: Control not inoculated
Number of subjects: 0
Study 27665372 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control (target diastolic blood pressure, 85mmHg)
Number of subjects: 911
Study 27665372 — intervention group
Group type: COMPARATOR
Intervention: Less tight control (target diastolic blood pressure, 100mmHg)
Number of subjects: 911
Study 27665372 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight control
Number of subjects: 911
Study 25703857 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised intervention programme delivered by a psychologist
Number of subjects: 40
Study 25703857 — intervention group
Group type: COMPARATOR
Intervention: Standard support (Control)
Number of subjects: 40
Study 24072034 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) for 7 weeks, performed 3 days/week.
Number of subjects: 26
Study 24072034 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute resistance exercise (ARE) at 60% of 1-RM for three sets of 8-12 repetitions.
Number of subjects: 26
Study 20538119 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual thrombus score > or = 3
Number of subjects: 91
Study 20538119 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger postprocedural reference vessel diameter
Number of subjects: 91
Study 17879117 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed completion axillary lymph node dissection (two-step ALND)
Number of subjects: 179
Study 17879117 — intervention group
Group type: COMPARATOR
Intervention: Immediate axillary lymph node dissection (one-step ALND)
Number of subjects: 179
Study 16374169 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based learning (SIM)
Number of subjects: 31
Study 16374169 — intervention group
Group type: COMPARATOR
Intervention: Problem-based learning (PBL)
Number of subjects: 31
Study 12846775 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-leaking dialyzers (BK-F series; Toray, Japan) for 6 months
Number of subjects: 13
Study 12846775 — intervention group
Group type: COMPARATOR
Intervention: Conventional non-protein-leaking dialyzers
Number of subjects: 13
Study 11039202 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN a-2 monotherapy (10 million I.U. in 50 ml physiological saline)
Number of subjects: 33
Study 11039202 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN a-2 + Farmarubicin (FRC) combination (50 mg in 50 ml physiological saline)
Number of subjects: 33
Study 11039202 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN a-2 monotherapy and IFN a-2 + FRC combination (Group I + II)
Number of subjects: 33
Study 11039202 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control Group III)
Number of subjects: 33
Study 8657529 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 228
Study 8657529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 1603897 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 1603897 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study 1603897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3932142 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 106
Study 3932142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Number of subjects: 106
Study 31523892 — intervention group
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (5, 10, 20, 30, and 40 mg)
Number of subjects: 462
Study 31523892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 31523892 — intervention group
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate
Number of subjects: 462
Study 29313134 — intervention group
Group type: EXPERIMENTAL
Intervention: Zataria multiflora (ZM) extract mouthwash
Number of subjects: 63
Study 29313134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 27776504 — intervention group
Group type: EXPERIMENTAL
Intervention: SoCog Mental‐State Reasoning Training (SoCog‐MSRT)
Number of subjects: 31
Study 27776504 — intervention group
Group type: EXPERIMENTAL
Intervention: SoCog Emotion Recognition Training (SoCog‐ERT)
Number of subjects: 31
Study 25332327 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 403
Study 25332327 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 403
Study 25332327 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients without zinc
Number of subjects: 403
Study 25332327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study 21817091 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic learning task
Number of subjects: 67
Study 21817091 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity between the ventral striatum and the medial prefrontal cortex
Number of subjects: 67
Study 19967441 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment (CBT)
Number of subjects: 27
Study 18044259 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g ascorbic acid
Number of subjects: 143
Study 18044259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 18044259 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 143
Study 16061568 — intervention group
Group type: EXPERIMENTAL
Intervention: Broselow cart
Number of subjects: 21
Study 16061568 — intervention group
Group type: COMPARATOR
Intervention: Standard cart
Number of subjects: 21
Study 11875333 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (0.025 mg/day) and norethisterone acetate (0.125 mg/day)
Number of subjects: 266
Study 10435260 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard program (longer inpatient treatment)
Number of subjects: 0
Study 10435260 — intervention group
Group type: COMPARATOR
Intervention: Abbreviated Inpatient program (shorter inpatient treatment)
Number of subjects: 0
Study 7787134 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide controlled release formulation (FR) with breakfast
Number of subjects: 28
Study 7787134 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide controlled release formulation (LR) with breakfast
Number of subjects: 28
Study 7787134 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide controlled release formulation (FR) fasting
Number of subjects: 28
Study 7787134 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide controlled release formulation (LR) fasting
Number of subjects: 28
Study 7787134 — intervention group
Group type: EXPERIMENTAL
Intervention: Total furosemide absorbed
Number of subjects: 28
Study 2186825 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm formula in trial A
Number of subjects: 777
Study 2186825 — intervention group
Group type: COMPARATOR
Intervention: Banked donor milk or preterm formula as sole diet or supplement to mother's expressed breast milk in trial A
Number of subjects: 777
Study 2186825 — intervention group
Group type: EXPERIMENTAL
Intervention: Term or preterm formula in trial B
Number of subjects: 777
Study 203635 — intervention group
Group type: EXPERIMENTAL
Intervention: BRL 5907 (5 mg per day for three days)
Number of subjects: 0
Study 203635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30888736 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoVas sirolimus-eluting bioresorbable scaffold (BRS)
Number of subjects: 1103
Study 28580708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT) 24 IU
Number of subjects: 192
Study 28580708 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 192
Study 25721787 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH; 20mg)
Number of subjects: 34
Study 25721787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 23685325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful eating workshop
Number of subjects: 102
Study 23685325 — intervention group
Group type: COMPARATOR
Intervention: Educational video (Control)
Number of subjects: 102
Study 21300350 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (10mg daily for 30 days)
Number of subjects: 50
Study 21300350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19460446 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 13
Study 19460446 — intervention group
Group type: COMPARATOR
Intervention: Normal wakefulness
Number of subjects: 13
Study 16721398 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat cheese enriched with 2 g of plant stanols per day
Number of subjects: 67
Study 16721398 — intervention group
Group type: COMPARATOR
Intervention: Control cheese with no plant stanols
Number of subjects: 67
Study 15201248 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral dose of oestradiol
Number of subjects: 34
Study 15201248 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oestradiol orally/day for 12 weeks
Number of subjects: 34
Study 15201248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11167171 — intervention group
Group type: EXPERIMENTAL
Intervention: isobaric mepivacaine 20 mg/ml
Number of subjects: 80
Study 11167171 — intervention group
Group type: COMPARATOR
Intervention: isobaric lidocaine 20 mg/ml
Number of subjects: 80
Study 9315790 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide inhalation aerosol (TAA) 200 microg (1 puff bid)
Number of subjects: 285
Study 9315790 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide inhalation aerosol (TAA) 400 microg (2 puffs bid)
Number of subjects: 285
Study 9315790 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide inhalation aerosol (TAA) 800 microg (4 puffs bid)
Number of subjects: 285
Study 9315790 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide inhalation aerosol (TAA) 1600 microg (8 puffs bid)
Number of subjects: 285
Study 9315790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 8361220 — intervention group
Group type: COMPARATOR
Intervention: Cranial irradiation with 18Gy
Number of subjects: 994
Study 8361220 — intervention group
Group type: COMPARATOR
Intervention: Cranial irradiation with 24Gy
Number of subjects: 994
Study 8361220 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with three drugs, CNS protection with cranial irradiation 18Gy or 24Gy, maintenance therapy for 120 weeks (GBTLI-80)
Number of subjects: 994
Study 8361220 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with three drugs, CNS protection with cranial irradiation 18Gy or 24Gy, continuous maintenance for 2 years (GBTLI-82)
Number of subjects: 994
Study 8361220 — intervention group
Group type: EXPERIMENTAL
Intervention: No cranial radiation, CNS protection with triple intrathecal therapy, consolidation therapy with high dose ARA-C for high risk patients (GBTLI-85)
Number of subjects: 994
Study 2940953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (200 mg by spinhaler) + Atropine sulfate (2.0 mg by nebulizer)
Number of subjects: 9